Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Janssen Research & Development, LLC
EIR
•Janssen Research & Development, LLC•February 4, 2019

Janssen Research & Development, LLC – FDA EIR, Feb 4, 2019

Record Details

A routine FDA inspection of Janssen Research & Development, LLC was conducted from January 22 to February 4, 2019, in Titusville, NJ. The inspection aimed to assess the company's compliance with applicable regulations, specifically the Sponsor, Contract Research Organizations and Monitors Compliance Program Guidance Manual (CPGM) 7348.810, across three clinical protocols for intranasal Esketamine in treatment-resistant depression. Despite a comprehensive review of operational aspects, including training, SOPs, vendor oversight, and data management, the inspection concluded without the issuance of a Form FDA 483, Inspectional Observations, indicating no significant regulatory violations requiring formal action. However, the inspection highlighted several operational challenges that Janssen was actively addressing. These included a notable number of intranasal device malfunctions leading to partial dose delivery for subjects, and instances where clinical investigators at one site failed to properly oversee drug dispensing, resulting in unrecorded partial doses. Another issue involved the administration of an incorrect investigational product kit at a different site. Initial discrepancies in electronic data audit trails were also noted but were clarified during the inspection. Janssen responded to these findings by implementing internal retraining for site staff on device usage and administration procedures, and conducting ongoing investigations into device complaints and administration errors. No specific corrective actions were formally mandated by the FDA in this report.

Company
Janssen Research & Development, LLC
Inspection date
February 4, 2019
Product type
drugs
Office
Center for Drug Evaluation and Research
People
  • Bei Yu (issuing_officer)
  • Mathew Thomas (investigator)
  • Shirley S. Wen
View Company Profile

ID · 4477e295-2f78-47cb-9e7d-c075b9b5e907

Violation Codes1
21 CFR 312

Full citation text and observation details available on the Dashboard.

Other documents for Janssen Research & Development, LLC
  • EIR - 2017-11-21November 21, 2017
  • EIR - 2017-02-27February 27, 2017
  • EIR - 2015-08-19August 19, 2015

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Janssen Research & Development, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.